Service notifications for recommended Technology Appraisals (TAs)
Technology Appraisals are listed below in alphanumerical order with links to further information on the NICE website.
| Title | Description | Date added | Download |
|---|---|---|---|
| TA1040 | Service Notification - Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (review of TA762) | 10-06-2025 | DownloadPreview |
| TA1039 | Service Notification - Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over | 10-06-2025 | DownloadPreview |
| TA1038 | Service Notification Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years (review of TA742) | 10-06-2025 | DownloadPreview |
| TA1037 | Service Notification Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer | 10-06-2025 | DownloadPreview |
| TA1036 | Service Notification - Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment | 10-06-2025 | DownloadPreview |
| TA1026 | Service Notification Tirzepatide for managing overweight and obesity | 09-06-2025 | DownloadPreview |
| TA1034 | Service Notification Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years | 23-05-2025 | DownloadPreview |
| TA1035 | Service Notification Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease | 23-05-2025 | DownloadPreview |
| TA1031 | Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over | 15-05-2025 | DownloadPreview |
| TA1030 | Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer | 15-05-2025 | DownloadPreview |
| TA1027 | Tebentafusp for treating advanced uveal melanoma | 15-05-2025 | DownloadPreview |
| TA1025 | Service Notification Ublituximab for treating relapsing multiple sclerosis | 18-04-2025 | DownloadPreview |
| TA1023 | Service Notification Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | 18-04-2025 | DownloadPreview |
| TA1019 | Service Notification Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over | 26-03-2025 | DownloadPreview |
| TA1022 | Service Notification Bevacizumab gamma for treating wet age-related macular degeneration | 26-03-2025 | DownloadPreview |
| TA1021 (review of TA529) | Service Notification Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer | 26-03-2025 | DownloadPreview |
| TA1016 | Service Notification Elafibranor for previously treated primary biliary cholangitis | 26-03-2025 | DownloadPreview |
| TA1018 (review of TA756) | Service Notification Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis | 26-03-2025 | DownloadPreview |
| TA1033 | Service Notification-Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over NOT RECOMMENDED | 24-03-2025 | DownloadPreview |
| TA1012 | Service Notification Avapritinib for treating advanced systemic mastocytosis | 14-03-2025 | DownloadPreview |